Scotland · NHS Scotland MSAN
Exenatide (Bydureon® BCise®) 2mg/0.85ml prolonged-release suspension for
MSAN(2025)48 · Level 2 · issued 27 Oct 2025
What the notice states
The supply position for each affected product, as recorded in the notice — read the full signed PDF above for the clinical advice and actions.
| Product | Position | Resupply |
|---|---|---|
| Valid until: noted product have been discontinued | Discontinued | — |
| pens have been discontinued with supplies now exhausted. | Discontinued | — |
| 2. Alternative GLP-1 RAs and dual GIP/GLP-1 RA remain available and can support increased | Available | — |
| you need to register with the SPS website. Registration for access to the website is available to | Available | — |
Provenance
Where this record's bytes came from and when they entered the record. The same fields ship with every API record (/api), so a citation can be checked against the capture. Internet-Archive recoveries are dated by the Archive's capture, never ours.
scot:msan:2025:48
- Recorded
- 06 Aug 2026 21:25 UTC
- Capture route
- Captured first-hand by ShortageSignal's scheduled check
- Read from
- NHS Scotland Medicine Supply Alert Notice (PDF)
- Captured at
- 06 Aug 2026 21:25 UTC
- Content hash
bfecfe6364c5a7872fe21c720ae563253b23c6df044fd390228b9e991fdaeff6sha256 of the captured bytes — proves what was captured, not that the source was correct- Source document
- https://www.publications.scot.nhs.uk/files/msan-2025-48.pdf ↗
From the NHS Scotland notice PDF (linked above); dates and “valid until” text are as stated, fuzzy wording kept as written. Scotland is covered separately from England — see methodology. Not an official NHS service, and not clinical advice — follow the guidance issued to your pharmacy.